KCNQ2 and amyotrophic lateral sclerosis: Here, we evaluated whetherthe simultaneous activation of two complementary targets, the voltage-gatedpotassium channels 7.2/3 (Kv7.2/3) and the mitochondrial translocatorprotein (TSPO), by a novel synthesized compound (GRT-X) is an effectiveneuroprotective treatment in ALS in vitro models.